Amedeo Smart

Free Medical Literature Service


 

Amedeo

Epilepsy

  Free Subscription

Articles published in
Eur J Clin Pharmacol
    January 2021
  1. GU X, Zhu M, Sheng C, Yu S, et al
    Population pharmacokinetics of unbound valproic acid in pediatric epilepsy patients in China: a protein binding model.
    Eur J Clin Pharmacol. 2021 Jan 10. pii: 10.1007/s00228-020-03080.
    >> Share

    August 2020
  2. YOON HY, Ahn MH, Yee J, Lee N, et al
    Influence of CYP2C9 and CYP2A6 on plasma concentrations of valproic acid: a meta-analysis.
    Eur J Clin Pharmacol. 2020;76:1053-1058.
    >> Share

    August 2019
  3. BAFTIU A, Lima MH, Svendsen K, Larsson PG, et al
    Safety aspects of antiepileptic drugs-a population-based study of adverse effects relative to changes in utilisation.
    Eur J Clin Pharmacol. 2019;75:1153-1160.
    >> Share

    January 2019
  4. SHI L, Zhu M, Li H, Wen Z, et al
    SCN1A and SCN2A polymorphisms are associated with response to valproic acid in Chinese epilepsy patients.
    Eur J Clin Pharmacol. 2019 Jan 28. pii: 10.1007/s00228-019-02633.
    >> Share

  5. MANOHARAN A, Kumar AS, Sreedevi A, Sathishkannan AD, et al
    HLA-B*5701 and HLA-B*5801 in an Indian patient with anti-epileptics induced cutaneous adverse drug reactions.
    Eur J Clin Pharmacol. 2019 Jan 4. pii: 10.1007/s00228-018-02618.
    >> Share

    November 2018
  6. LIN WW, Li XW, Jiao Z, Zhang J, et al
    Population pharmacokinetics of oxcarbazepine active metabolite in Chinese paediatric epilepsy patients and its application in individualised dosage regimens.
    Eur J Clin Pharmacol. 2018 Nov 19. pii: 10.1007/s00228-018-2600.
    >> Share

    April 2018
  7. MEI S, Feng W, Zhu L, Li X, et al
    Effect of CYP2C19, UGT1A8, and UGT2B7 on valproic acid clearance in children with epilepsy: a population pharmacokinetic model.
    Eur J Clin Pharmacol. 2018 Apr 17. pii: 10.1007/s00228-018-2440.
    >> Share

  8. WANG P, Lin XQ, Cai WK, Xu GL, et al
    Effect of UGT2B7 genotypes on plasma concentration of valproic acid: a meta-analysis.
    Eur J Clin Pharmacol. 2018;74:433-442.
    >> Share

    March 2018
  9. RODRIGUES C, Chhun S, Chiron C, Dulac O, et al
    A population pharmacokinetic model taking into account protein binding for the sustained-release granule formulation of valproic acid in children with epilepsy.
    Eur J Clin Pharmacol. 2018 Mar 21. pii: 10.1007/s00228-018-2444.
    >> Share

    February 2018
  10. KHELOUFI F, Default A, Perrouty B, Blin O, et al
    Perampanel-associated self-harm ideation after dosage increase.
    Eur J Clin Pharmacol. 2018;74:243-244.
    >> Share

    January 2018
  11. MORATH B, Green K, Zaradzki M, Heid J, et al
    Subtherapeutic valproic acid plasma concentrations under concomitant dipyrone therapy in an epilepsy patient-a case report.
    Eur J Clin Pharmacol. 2018 Jan 23. pii: 10.1007/s00228-018-2417.
    >> Share

  12. XU S, Liu L, Chen Y, Liu M, et al
    Population pharmacokinetics of lamotrigine co-administered with valproic acid in Chinese epileptic children using nonlinear mixed effects modeling.
    Eur J Clin Pharmacol. 2018 Jan 16. pii: 10.1007/s00228-018-2414.
    >> Share

    April 2017
  13. BAFTIU A, Landmark CJ, Rusten IR, Feet SA, et al
    Erratum to: Changes in utilisation of antiepileptic drugs in epilepsy and non-epilepsy disorders-A pharmacoepidemiological study and clinical implications.
    Eur J Clin Pharmacol. 2017 Apr 7. doi: 10.1007/s00228-017-2252.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016